Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

RVL PHARMACEUTICALS PLC

(RVLP)
  Report
Delayed Nasdaq  -  04:00 2022-11-28 pm EST
1.390 USD   -5.44%
11/10RVL PHARMACEUTICALS PLC Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
11/10Transcript : RVL Pharmaceuticals plc, Q3 2022 Earnings Call, Nov 10, 2022
CI
11/10Earnings Flash (RVLP) RVL PHARMACEUTICALS Posts Q3 Revenue $10M
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds

Earnings Flash (RVLP) RVL PHARMACEUTICALS Reports Q2 Revenue $8.4M, vs. Street Est of $8.52M

08/11/2022 | 06:53am EST


ę MT Newswires 2022
All news about RVL PHARMACEUTICALS PLC
11/10RVL PHARMACEUTICALS PLC Management's Discussion and Analysis of Financial Condition an..
AQ
11/10Transcript : RVL Pharmaceuticals plc, Q3 2022 Earnings Call, Nov 10, 2022
CI
11/10Earnings Flash (RVLP) RVL PHARMACEUTICALS Posts Q3 Revenue $10M
MT
11/10RVL Pharmaceuticals plc Reports Third Quarter 2022 Financial Results; Provides Commerci..
AQ
11/10RVL Pharmaceuticals plc Reports Earnings Results for the Third Quarter and Nine Months ..
CI
11/10RVL Pharmaceuticals plc Reaffirms Sales Guidance for the Fourth Quarter of 2022
CI
11/03RVL Pharmaceuticals plc to Discuss Third Quarter 2022 Financial Results and Provide Com..
AQ
10/25Barclays Adjusts Price Target on RVL Pharmaceuticals to $3 From $4, Reiterates Overweig..
MT
10/21Jefferies Assumes RVL Pharmaceuticals at Hold With $2.50 Price Target
MT
10/18RVL Pharmaceuticals Expects 19% Sequential Increase in Upneeq Product Q3 Sales
MT
More news
Analyst Recommendations on RVL PHARMACEUTICALS PLC
More recommendations
Financials (USD)
Sales 2022 52,6 M - -
Net income 2022 -49,3 M - -
Net Debt 2022 - - -
P/E ratio 2022 -2,53x
Yield 2022 -
Capitalization 138 M 138 M -
Capi. / Sales 2022 2,62x
Capi. / Sales 2023 1,94x
Nbr of Employees 156
Free-Float 48,9%
Chart RVL PHARMACEUTICALS PLC
Duration : Period :
RVL Pharmaceuticals plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RVL PHARMACEUTICALS PLC
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 1,39 $
Average target price 3,72 $
Spread / Average Target 168%
EPS Revisions
Managers and Directors
Brian A. Markison Chairman, Chief Executive & Financial Officer
Tina Devries Executive VP-Research & Development
James Schaub Chief Operating Officer & Executive Vice President
Sergio Alegre Vice President-Global Compliance
David Fredrick Burgstahler Independent Director
Sector and Competitors